Review

mouse elane elisa kit (Elabscience Biotechnology)

Elabscience Biotechnology is a verified supplier

Elabscience Biotechnology manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Elabscience Biotechnology mouse elane elisa kit

Fig. 2 <t>Elane</t> induces ferroptosis in the hepatocytes of MAFLD mice. A Primary mouse hepatocytes were extracted and treated with FFA (1 mM, OA:PA = 2:1) for 24 h with or without Elane (3 μg/mL), and the ROS levels in each group were assessed by ﬂow cytometry (n = 3). B MDA levels in each group after FFA and/or Elane treatment (n = 3). C Flow cytometry was used to determine C11-BODIPY levels after FFA and/or Elane treatment (n = 3). D Western blotting for 4-hne protein levels after FFA and/or Elane treatment and grayscale analysis (n = 3). E Transmission electron microscopy was used to observe mitochondrial changes in cells after FFA and/or Elane treatment. F Cells were treated with the ferroptosis inhibitor Fer-1 (10 μM), and cell viability was assayed by a CCK-8 assay (n = 3). G Primary hepatocytes were extracted from Elane+/+ and Elane−/−mice after modelling, and ROS levels were assessed in each group by ﬂow cytometry (n = 3). H MDA levels in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). I Flow cytometry analysis of C11-BODIPY levels in primary hepatocytes after modelling in Elane+/+ and Elane-/- mice (n = 3). J Transmission electron microscopy was used to observe mitochondrial changes in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice. Scale bars: 500 nm. The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Mouse Elane Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse elane elisa kit/product/Elabscience Biotechnology
Average 93 stars, based on 10 article reviews

mouse elane elisa kit - by Bioz Stars, 2026-06

93/100 stars

Images

1) Product Images from "ELANE enhances KEAP1 protein stability and reduces NRF2-mediated ferroptosis inhibition in metabolic dysfunction-associated fatty liver disease."

Article Title: ELANE enhances KEAP1 protein stability and reduces NRF2-mediated ferroptosis inhibition in metabolic dysfunction-associated fatty liver disease.

Journal: Cell death & disease

doi: 10.1038/s41419-025-07603-2

Fig. 2 Elane induces ferroptosis in the hepatocytes of MAFLD mice. A Primary mouse hepatocytes were extracted and treated with FFA (1 mM, OA:PA = 2:1) for 24 h with or without Elane (3 μg/mL), and the ROS levels in each group were assessed by ﬂow cytometry (n = 3). B MDA levels in each group after FFA and/or Elane treatment (n = 3). C Flow cytometry was used to determine C11-BODIPY levels after FFA and/or Elane treatment (n = 3). D Western blotting for 4-hne protein levels after FFA and/or Elane treatment and grayscale analysis (n = 3). E Transmission electron microscopy was used to observe mitochondrial changes in cells after FFA and/or Elane treatment. F Cells were treated with the ferroptosis inhibitor Fer-1 (10 μM), and cell viability was assayed by a CCK-8 assay (n = 3). G Primary hepatocytes were extracted from Elane+/+ and Elane−/−mice after modelling, and ROS levels were assessed in each group by ﬂow cytometry (n = 3). H MDA levels in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). I Flow cytometry analysis of C11-BODIPY levels in primary hepatocytes after modelling in Elane+/+ and Elane-/- mice (n = 3). J Transmission electron microscopy was used to observe mitochondrial changes in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice. Scale bars: 500 nm. The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Figure Legend Snippet: Fig. 2 Elane induces ferroptosis in the hepatocytes of MAFLD mice. A Primary mouse hepatocytes were extracted and treated with FFA (1 mM, OA:PA = 2:1) for 24 h with or without Elane (3 μg/mL), and the ROS levels in each group were assessed by ﬂow cytometry (n = 3). B MDA levels in each group after FFA and/or Elane treatment (n = 3). C Flow cytometry was used to determine C11-BODIPY levels after FFA and/or Elane treatment (n = 3). D Western blotting for 4-hne protein levels after FFA and/or Elane treatment and grayscale analysis (n = 3). E Transmission electron microscopy was used to observe mitochondrial changes in cells after FFA and/or Elane treatment. F Cells were treated with the ferroptosis inhibitor Fer-1 (10 μM), and cell viability was assayed by a CCK-8 assay (n = 3). G Primary hepatocytes were extracted from Elane+/+ and Elane−/−mice after modelling, and ROS levels were assessed in each group by ﬂow cytometry (n = 3). H MDA levels in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). I Flow cytometry analysis of C11-BODIPY levels in primary hepatocytes after modelling in Elane+/+ and Elane-/- mice (n = 3). J Transmission electron microscopy was used to observe mitochondrial changes in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice. Scale bars: 500 nm. The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Techniques Used: Cytometry, Flow Cytometry, Western Blot, Transmission Assay, Electron Microscopy, CCK-8 Assay, Comparison, Control

Fig. 3 Elane regulates ferroptosis in hepatocytes via Gpx4. A Immunohistochemistry staining was used to assess Gpx4 expression in liver tissue after modelling in Elane+/+ and Elane−/−mice (n = 3). Scale bars: 100 μm. B, C Western blotting was used to assess Gpx4 protein expression in liver tissues after modelling in Elane+/+ and Elane−/−mice, and a graded analysis was performed (n = 3). D qRT‒PCR was used to assess the mRNA expression of Gpx4 in the liver tissues of Elane+/+ and Elane−/−mice after modelling (n = 3). E Extraction of protein from primary mouse hepatocytes, followed by Western blotting to assess Gpx4 protein levels after FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). F, G Western blotting was used to assess Gpx4 protein levels after the overexpression of Gpx4 by FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). H MDA levels after the overexpression of Gpx4 following FFA and/or Elane treatment (n = 3). I CCK-8 was used to assess cell viability after the overexpression of Gpx4 after FFA and/or Elane treatment (n = 3). J, K Extraction of protein from primary hepatocytes from Elane+/+ and Elane−/−mice after modelling, followed by Western blotting to assess Gpx4 protein expression, after which grayscale analysis was performed (n = 3). L MDA levels in primary hepatocytes from Elane+/+ and Elane−/−mice after modelling were assessed after 24 h of treatment with the Gpx4 inhibitor RSL3 (2 μM) (n = 3). M Cell viability of primary hepatocytes after modelling in Elane+/+ and Elane−/−mice was assayed by CCK-8 after the addition of RSL3 for 24 h (n = 3). The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Figure Legend Snippet: Fig. 3 Elane regulates ferroptosis in hepatocytes via Gpx4. A Immunohistochemistry staining was used to assess Gpx4 expression in liver tissue after modelling in Elane+/+ and Elane−/−mice (n = 3). Scale bars: 100 μm. B, C Western blotting was used to assess Gpx4 protein expression in liver tissues after modelling in Elane+/+ and Elane−/−mice, and a graded analysis was performed (n = 3). D qRT‒PCR was used to assess the mRNA expression of Gpx4 in the liver tissues of Elane+/+ and Elane−/−mice after modelling (n = 3). E Extraction of protein from primary mouse hepatocytes, followed by Western blotting to assess Gpx4 protein levels after FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). F, G Western blotting was used to assess Gpx4 protein levels after the overexpression of Gpx4 by FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). H MDA levels after the overexpression of Gpx4 following FFA and/or Elane treatment (n = 3). I CCK-8 was used to assess cell viability after the overexpression of Gpx4 after FFA and/or Elane treatment (n = 3). J, K Extraction of protein from primary hepatocytes from Elane+/+ and Elane−/−mice after modelling, followed by Western blotting to assess Gpx4 protein expression, after which grayscale analysis was performed (n = 3). L MDA levels in primary hepatocytes from Elane+/+ and Elane−/−mice after modelling were assessed after 24 h of treatment with the Gpx4 inhibitor RSL3 (2 μM) (n = 3). M Cell viability of primary hepatocytes after modelling in Elane+/+ and Elane−/−mice was assayed by CCK-8 after the addition of RSL3 for 24 h (n = 3). The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Techniques Used: Immunohistochemistry, Staining, Expressing, Western Blot, Extraction, Over Expression, CCK-8 Assay, Comparison, Control

Fig. 5 Elane inhibits the degradation of Keap1. A qRT‒PCR was used to assess Keap1 mRNA expression in primary hepatocytes after FFA and/or Elane treatment (n = 3). B qRT‒PCR was used to assess the mRNA half-life of Keap1 after FFA and/or Elane treatment of primary hepatocytes (n = 3). C, D Western blotting was used to assess the protein half-life of Keap1 after FFA and/or Elane treatment of primary hepatocytes (n = 3). E qRT‒PCR was used to assess the mRNA expression of Keap1 in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). F qRT‒PCR was used to assess the mRNA half-life of Keap1 in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). G, H Western blotting was used to assess the protein half-life of Keap1 in primary hepatocytes after modelling in Elane+/ + and Elane−/−mice (n = 3). I, J After MG132 (10 μM) was added for 4 h, Western blotting was performed to assess the protein expression of Keap1 after FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). K, L After the addition of CQ (20 μM) for 8 h, Western blotting was performed to assess the protein expression of Keap1 after FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Figure Legend Snippet: Fig. 5 Elane inhibits the degradation of Keap1. A qRT‒PCR was used to assess Keap1 mRNA expression in primary hepatocytes after FFA and/or Elane treatment (n = 3). B qRT‒PCR was used to assess the mRNA half-life of Keap1 after FFA and/or Elane treatment of primary hepatocytes (n = 3). C, D Western blotting was used to assess the protein half-life of Keap1 after FFA and/or Elane treatment of primary hepatocytes (n = 3). E qRT‒PCR was used to assess the mRNA expression of Keap1 in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). F qRT‒PCR was used to assess the mRNA half-life of Keap1 in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). G, H Western blotting was used to assess the protein half-life of Keap1 in primary hepatocytes after modelling in Elane+/ + and Elane−/−mice (n = 3). I, J After MG132 (10 μM) was added for 4 h, Western blotting was performed to assess the protein expression of Keap1 after FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). K, L After the addition of CQ (20 μM) for 8 h, Western blotting was performed to assess the protein expression of Keap1 after FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Techniques Used: Expressing, Western Blot, Comparison, Control

Fig. 6 Elane attenuates P62 binding to Keap1 and increases Keap1 stability. A qRT‒PCR analysis of P62 mRNA expression in primary hepatocytes after FFA and/or Elane treatment (n = 3). B Western blotting for protein expression and grayscale analysis of P62 in primary hepatocytes after FFA and/or Elane treatment (n = 3). C qRT‒PCR was used to assess the mRNA expression of P62 in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). D Western blotting for protein expression and grayscale analysis of P62 in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). E, F Proteins were immunoprecipitated with Keap1 or P62 antibodies, and the binding of Keap1 and P62 proteins was assessed after FFA and/or Elane treatment of primary hepatocytes. G, H Binding of Keap1 and P62 proteins in primary hepatocytes after Elane+/+ and Elane−/−mouse models were established was assessed by immunoprecipitating the proteins with Keap1 or P62 antibodies. The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Figure Legend Snippet: Fig. 6 Elane attenuates P62 binding to Keap1 and increases Keap1 stability. A qRT‒PCR analysis of P62 mRNA expression in primary hepatocytes after FFA and/or Elane treatment (n = 3). B Western blotting for protein expression and grayscale analysis of P62 in primary hepatocytes after FFA and/or Elane treatment (n = 3). C qRT‒PCR was used to assess the mRNA expression of P62 in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). D Western blotting for protein expression and grayscale analysis of P62 in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). E, F Proteins were immunoprecipitated with Keap1 or P62 antibodies, and the binding of Keap1 and P62 proteins was assessed after FFA and/or Elane treatment of primary hepatocytes. G, H Binding of Keap1 and P62 proteins in primary hepatocytes after Elane+/+ and Elane−/−mouse models were established was assessed by immunoprecipitating the proteins with Keap1 or P62 antibodies. The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Techniques Used: Binding Assay, Expressing, Western Blot, Immunoprecipitation, Comparison, Control

Image Search Results

Journal: Cell death & disease

Article Title: ELANE enhances KEAP1 protein stability and reduces NRF2-mediated ferroptosis inhibition in metabolic dysfunction-associated fatty liver disease.

doi: 10.1038/s41419-025-07603-2

Figure Lengend Snippet: Fig. 2 Elane induces ferroptosis in the hepatocytes of MAFLD mice. A Primary mouse hepatocytes were extracted and treated with FFA (1 mM, OA:PA = 2:1) for 24 h with or without Elane (3 μg/mL), and the ROS levels in each group were assessed by ﬂow cytometry (n = 3). B MDA levels in each group after FFA and/or Elane treatment (n = 3). C Flow cytometry was used to determine C11-BODIPY levels after FFA and/or Elane treatment (n = 3). D Western blotting for 4-hne protein levels after FFA and/or Elane treatment and grayscale analysis (n = 3). E Transmission electron microscopy was used to observe mitochondrial changes in cells after FFA and/or Elane treatment. F Cells were treated with the ferroptosis inhibitor Fer-1 (10 μM), and cell viability was assayed by a CCK-8 assay (n = 3). G Primary hepatocytes were extracted from Elane+/+ and Elane−/−mice after modelling, and ROS levels were assessed in each group by ﬂow cytometry (n = 3). H MDA levels in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). I Flow cytometry analysis of C11-BODIPY levels in primary hepatocytes after modelling in Elane+/+ and Elane-/- mice (n = 3). J Transmission electron microscopy was used to observe mitochondrial changes in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice. Scale bars: 500 nm. The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Article Snippet: The levels of Elane in the tissue homogenate and plasma from different groups were quantified with a mouse Elane ELISA kit (E-EL-M3025, Elabscience) following the manufacturer’s instructions.

Techniques: Cytometry, Flow Cytometry, Western Blot, Transmission Assay, Electron Microscopy, CCK-8 Assay, Comparison, Control

Journal: Cell death & disease

Article Title: ELANE enhances KEAP1 protein stability and reduces NRF2-mediated ferroptosis inhibition in metabolic dysfunction-associated fatty liver disease.

doi: 10.1038/s41419-025-07603-2

Figure Lengend Snippet: Fig. 3 Elane regulates ferroptosis in hepatocytes via Gpx4. A Immunohistochemistry staining was used to assess Gpx4 expression in liver tissue after modelling in Elane+/+ and Elane−/−mice (n = 3). Scale bars: 100 μm. B, C Western blotting was used to assess Gpx4 protein expression in liver tissues after modelling in Elane+/+ and Elane−/−mice, and a graded analysis was performed (n = 3). D qRT‒PCR was used to assess the mRNA expression of Gpx4 in the liver tissues of Elane+/+ and Elane−/−mice after modelling (n = 3). E Extraction of protein from primary mouse hepatocytes, followed by Western blotting to assess Gpx4 protein levels after FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). F, G Western blotting was used to assess Gpx4 protein levels after the overexpression of Gpx4 by FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). H MDA levels after the overexpression of Gpx4 following FFA and/or Elane treatment (n = 3). I CCK-8 was used to assess cell viability after the overexpression of Gpx4 after FFA and/or Elane treatment (n = 3). J, K Extraction of protein from primary hepatocytes from Elane+/+ and Elane−/−mice after modelling, followed by Western blotting to assess Gpx4 protein expression, after which grayscale analysis was performed (n = 3). L MDA levels in primary hepatocytes from Elane+/+ and Elane−/−mice after modelling were assessed after 24 h of treatment with the Gpx4 inhibitor RSL3 (2 μM) (n = 3). M Cell viability of primary hepatocytes after modelling in Elane+/+ and Elane−/−mice was assayed by CCK-8 after the addition of RSL3 for 24 h (n = 3). The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Techniques: Immunohistochemistry, Staining, Expressing, Western Blot, Extraction, Over Expression, CCK-8 Assay, Comparison, Control

Journal: Cell death & disease

Article Title: ELANE enhances KEAP1 protein stability and reduces NRF2-mediated ferroptosis inhibition in metabolic dysfunction-associated fatty liver disease.

doi: 10.1038/s41419-025-07603-2

Figure Lengend Snippet: Fig. 5 Elane inhibits the degradation of Keap1. A qRT‒PCR was used to assess Keap1 mRNA expression in primary hepatocytes after FFA and/or Elane treatment (n = 3). B qRT‒PCR was used to assess the mRNA half-life of Keap1 after FFA and/or Elane treatment of primary hepatocytes (n = 3). C, D Western blotting was used to assess the protein half-life of Keap1 after FFA and/or Elane treatment of primary hepatocytes (n = 3). E qRT‒PCR was used to assess the mRNA expression of Keap1 in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). F qRT‒PCR was used to assess the mRNA half-life of Keap1 in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). G, H Western blotting was used to assess the protein half-life of Keap1 in primary hepatocytes after modelling in Elane+/ + and Elane−/−mice (n = 3). I, J After MG132 (10 μM) was added for 4 h, Western blotting was performed to assess the protein expression of Keap1 after FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). K, L After the addition of CQ (20 μM) for 8 h, Western blotting was performed to assess the protein expression of Keap1 after FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Techniques: Expressing, Western Blot, Comparison, Control

Journal: Cell death & disease

Article Title: ELANE enhances KEAP1 protein stability and reduces NRF2-mediated ferroptosis inhibition in metabolic dysfunction-associated fatty liver disease.

doi: 10.1038/s41419-025-07603-2

Figure Lengend Snippet: Fig. 6 Elane attenuates P62 binding to Keap1 and increases Keap1 stability. A qRT‒PCR analysis of P62 mRNA expression in primary hepatocytes after FFA and/or Elane treatment (n = 3). B Western blotting for protein expression and grayscale analysis of P62 in primary hepatocytes after FFA and/or Elane treatment (n = 3). C qRT‒PCR was used to assess the mRNA expression of P62 in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). D Western blotting for protein expression and grayscale analysis of P62 in primary hepatocytes after modelling in Elane+/+ and Elane−/−mice (n = 3). E, F Proteins were immunoprecipitated with Keap1 or P62 antibodies, and the binding of Keap1 and P62 proteins was assessed after FFA and/or Elane treatment of primary hepatocytes. G, H Binding of Keap1 and P62 proteins in primary hepatocytes after Elane+/+ and Elane−/−mouse models were established was assessed by immunoprecipitating the proteins with Keap1 or P62 antibodies. The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not signiﬁcant.

Techniques: Binding Assay, Expressing, Western Blot, Immunoprecipitation, Comparison, Control

Review

Structured Review

Images

1) Product Images from "ELANE enhances KEAP1 protein stability and reduces NRF2-mediated ferroptosis inhibition in metabolic dysfunction-associated fatty liver disease."

Similar Products

Image Search Results